COVID-19 S protein human adenovirus-vectored (Ad26.COV2.S) vaccine, recombinant

Generic Medicine Info
Indications and Dosage
Active immunisation against coronavirus disease 2019 (COVID-19)
Adult: Primary vaccination: 50 billion viral particles/0.5 mL as a single dose. Booster dose: 1st booster dose: 50 billion viral particles/0.5 mL as a single dose, to be given ≥2 months after the completion of the primary vaccination with Ad26.COV2.S vaccine (homologous booster dose). Alternatively, 50 billion viral particles/0.5 mL as a single dose may be given following the completion of the primary series with an authorised or approved COVID-19 vaccine (heterologous booster dose); the dosing interval for the heterologous booster dose is the same as that authorised for a booster dose of the vaccine used for primary series. Ad26.COV2.S vaccine should not be used as a 2nd booster dose. Doses are injected preferably in the deltoid muscle. Recommendations and approval of booster doses may vary between countries. Refer to specific country guidelines.
Elderly: No dosage adjustment required.
Child: <18 years Currently, the safety and efficacy of administering Ad26.COV2.S vaccine in children and adolescents has not been established; until such data are available, vaccination in this age group is not recommended.
Special Patient Group
For moderately or severely immunocompromised patients ≥18 years: Primary vaccination: 50 billion viral particles/0.5 mL as a single dose. Thereafter an additional (2nd) primary dose using a monovalent mRNA COVID-19 vaccine may be given ≥4 weeks after the 1st primary vaccination of Ad26.COV2.S vaccine. Booster dose: 1st booster dose: 50 billion viral particles/0.5 mL as a single dose of Ad26.COV2.S vaccine or a bivalent mRNA COVID-19 vaccine may be administered at least 2 months after the completion of the additional (2nd) primary dose. Recommendations and approval of booster doses may vary between countries. Refer to specific country guidelines.
History of severe hypersensitivity reaction (e.g. anaphylaxis) after a previous dose; known diagnosed allergy to any component of the formulation (e.g. polysorbate 80). History of confirmed thrombosis with thrombocytopenia syndrome after a previous dose of Ad26.COV2.S vaccine or any other adenovirus vector COVID-19 vaccine; history of capillary leak syndrome.
Special Precautions
Patient with history of bleeding disorder (e.g. thrombocytopenia, immune thrombocytopenia), any coagulation disorder (e.g. haemophilia), or risk factors for bleeding (receiving anticoagulant therapy); those who are at increased risk for venous thromboembolism; history of Guillain-Barre syndrome; history of non-severe, immediate (occurs within 4 hours) allergic reaction to a previous dose of Ad26.COV2.S vaccine; history of immediate allergic reaction to any other vaccine or injectable therapies (excluding SC immunotherapy for allergies) and to polyethylene glycol; contraindication to other types of COVID-19 vaccine (e.g. mRNA COVID-19 vaccine). Immunocompromised patients (e.g. those with HIV or receiving immunosuppressant treatment). Not recommended in patients who developed Guillain-Barre Syndrome within 6 weeks after a dose of Ad26.COV2.S vaccine. Individuals with a history of an immune-mediated syndrome characterised by thrombosis and thrombocytopenia (e.g. heparin-induced thrombocytopenia) are recommended to receive currently authorised or approved mRNA COVID-19 vaccine. In patients with history of multisystem inflammatory syndrome (MIS), may consider delaying the vaccination until clinical recovery. Defer administration of vaccine in patients with moderate to severe acute illness (with or without fever); vaccination may be given in patients with mild acute illness (with or without fever). Defer vaccine administration in patients with known current SARS-CoV-2 infection until recovery from acute illness (if symptomatic) and no longer need isolation. Consider delaying the primary vaccination or booster dose by 3 months from symptom onset or positive test (if asymptomatic) in patients who recently had SARS-CoV-2 infection. Not recommended for postexposure prophylaxis. Pregnancy and lactation.

It should be noted that:

- Refer to your local health authority for the most up-to-date therapeutic drug monitoring protocol when prescribing Ad26.COV2.S vaccine.
- The duration of protection against COVID-19 after a complete vaccination course has not been fully evaluated. Clinical trials and epidemiologic surveillance are ongoing to evaluate breakthrough infection in fully vaccinated individuals.
- Ad26.COV2.S vaccine may be available in some countries under an emergency use authorisation (EUA) or conditional approval scheme. Registration status and/or availability may vary between countries. Refer to your local regulatory agencies for more information.
- Administration of antipyretics, analgesics, or antihistamines prior to the administration of COVID-19 vaccines as prophylaxis for post-vaccination symptoms is not recommended. However, antipyretic/analgesic medications may be taken after vaccination to treat local/systemic post-vaccination symptoms (if medically appropriate).
- Individuals who have received a single dose of Ad26.COV2.S vaccine are considered to have a complete, valid primary vaccination against COVID-19.
- Recommendations and approval of booster doses (particularly in individuals with co-morbidities) may vary between countries. Refer to specific country guidelines.
- Minimise any unnecessary co-medication whenever possible, given the lack of information about interaction risk.
- Record the vaccine name, batch or lot number, expiration date, and other administration details clearly to improve the traceability of biological medicinal products.
- To alleviate the risks of this unapproved drug, local regulatory agencies may require healthcare facilities and healthcare providers to comply with certain regulations for the transport, storage, and administration of Ad26.COV2.S vaccine. Refer to country-specific recommendations for further information.
Adverse Reactions
Significant: Severe allergic reactions (including anaphylaxis); myocarditis, pericarditis; anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress-related reactions; shoulder injury (e.g. shoulder bursitis or tendinopathy) due to vaccine administration; transient contralateral or ipsilateral lymphadenopathy. Very rarely, Guillain-Barre syndrome (mainly in males), transverse myelitis.
Immune system disorders: Angioedema (without respiratory distress).
Ear and labyrinth disorders: Tinnitus.
Gastrointestinal disorders: Nausea, diarrhoea, vomiting.
General disorders and administration site conditions: Inj site pain, erythema or swelling; fatigue, asthenia, pyrexia, chills, malaise.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia, muscle weakness, pain in extremity, back pain.
Nervous system disorders: Headache, dizziness, tremor, paraesthesia, hypoaesthesia. Rarely, facial paralysis (including Bell's palsy).
Respiratory, thoracic and mediastinal disorders: Cough, sneezing, oropharyngeal pain.
Skin and subcutaneous tissue disorders: Urticaria, rash, hyperhidrosis.
Vascular disorders: Cutaneous small vessel vasculitis.
Potentially Fatal: Rarely, thrombosis with thrombocytopenia syndrome (primarily in females), including severe cases of thrombosis at unusual locations (e.g. cerebral venous sinus thrombosis, splanchnic vein thrombosis, portal vein thrombosis, arterial thrombosis); venous thromboembolism. Very rarely, immune thrombocytopenia, capillary leak syndrome.
Patient Counseling Information
Fully vaccinated recipients should continue to observe effective prevention measures (e.g. wearing a mask, social distancing). Refer to specific country guidelines. Vaccinated individuals should seek immediate medical attention if a few days after vaccination they develop the following: severe or persistent headaches, changes in mental status, blurred vision, seizures, shortness of breath, chest pain, leg swelling or pain, persistent abdominal pain, or any unusual skin bruising and/or petechiae beyond the site of vaccination.
Monitoring Parameters
Monitor for hypersensitivity reaction and syncope for at least 15 minutes post-vaccination. Observe patients for 30 minutes after vaccination in patients with a history of anaphylaxis (due to any cause), history of non-severe, immediate (within 4 hours) allergic reaction after receiving a previous dose of COVID-19 vaccine, history of immediate allergic reaction to any other vaccine or injectable therapy, and in patients with contraindication to a different type of COVID-19 vaccine. Actively investigate individuals diagnosed with thrombocytopenia within 3 weeks post-vaccination for signs of thrombosis. Additionally, patients who develop thrombosis within 3 weeks of vaccination must be assessed for thrombocytopenia. Closely monitor for signs and symptoms of thromboembolism and/or thrombocytopenia, Guillain-Barre syndrome, and transverse myelitis.
Drug Interactions
Therapeutic effect may be diminished by immunosuppressants. Prophylactic use of antihistamines may mask the cutaneous signs of anaphylaxis which may lead to delayed diagnosis and management.
Lab Interference
May cause false-positive rapid plasma reagin (RPR; nontreponemal [syphilis screening]) results for certain RPR tests for ≥5 months following vaccination. It is recommended to perform mammograms before vaccination to avoid possible misinterpretation of mammogram screening.
Mechanism of Action: COVID-19 S protein human adenovirus-vectored (Ad26.COV2.S) vaccine, recombinant is a monovalent vaccine composed of a recombinant, replication-incompetent human adenovirus type 26 vector that expresses SARS-CoV-2 spike (S) antigen without the propagation of the virus. Once administered, the vaccine then stimulates neutralising antibodies and cellular immune response directed against the S antigen, which may contribute to protection against COVID-19 disease.
Synonym: COVID-19 vaccine (Ad26.COV2.S [recombinant]).
Vaccines are initially stored frozen by the manufacturer, then may be supplied either frozen between -25 to -15°C or thawed between 2-8°C. Intact vial: If received a thawed vaccine: Store between 2-8°C. Alternatively, may store between 9-25°C for up to 12 hours. Do not freeze. Protect from light. If received a frozen vaccine: Thaw between 2-8°C for approx 13 hours (for 10 vials/carton) or approx 2 hours (for 1 vial) and if not used immediately, store between 2-8°C for a single period of up to 11 months (not exceeding the original expiry date). Protect from light. Alternatively, thaw at room temperature (≤25°C) for approx 4 hours (for 10 vials/carton) or approx 1 hour (for 1 vial); vaccines are stable for up to 12 hours between 9-25°C. Do not refreeze thawed vials. Do not shake. Opened vial (after the 1st needle puncture): Store between 2-8°C for up to 6 hours or at ≤25°C for up to 3 hours. This vaccine contains genetically modified organisms (GMO); follow applicable procedures for receiving, handling, administration, and disposal. Storage recommendations may vary among countries or between carton and vial labels of individual products. Refer to specific product or country guidelines.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BN02 - covid-19, viral vector, non-replicating ; Belongs to the class of covid-19 vaccines.
Anon. COVID-19 Vaccine (Adenovirus Vector). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 25/05/2023.

Anon. COVID-19 Vaccine, Viral Vector (Janssen). AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 05/05/2023.

COVID-19 Vaccine Janssen Suspension for Injection, COVID-19 Vaccine (Ad26.COV2.S [Recombinant]) (Janssen-Cilag Ltd). MHRA. Accessed 05/05/2023.

COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised. Centers for Disease Control and Prevention. Accessed 29/05/2023.

COVID-19 Vaccines Safety Update 03 August 2022. European Medicines Agency [online]. Accessed 05/09/2022.

Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19). U.S. FDA. Accessed 05/05/2023.

Interim Recommendations for the Use of the Janssen Ad26.COV2.S (COVID-19) Vaccine. World Health Organization. Accessed 05/09/2022.

Janssen COVID-19 Vaccine (Ad26.COV2.S) Injection, Suspension (Janssen Products, LP). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/05/2023.

Janssen-Cilag (New Zealand) Ltd. COVID-19 Vaccine Janssen Ad26.COV2.S data sheet 09 March 2023. Medsafe. Accessed 05/05/2023.

Jcovden Suspension for Injection, COVID-19 Vaccine (Ad26.COV2-S [recombinant]) (Janssen-Cilag International NV). European Medicines Agency [online]. Accessed 05/05/2023.

SARS-CoV-2 Virus (COVID-19) Adenovirus Vector Vaccine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. Accessed 25/05/2023.

Disclaimer: This information is independently developed by MIMS based on COVID-19 S protein human adenovirus-vectored (Ad26.COV2.S) vaccine, recombinant from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in